tiprankstipranks
Trending News
More News >
BioArctic AB Class B (SE:BIOA.B)
:BIOA.B
Advertisement

BioArctic AB Class B (BIOA.B) AI Stock Analysis

Compare
3 Followers

Top Page

SE:BIOA.B

BioArctic AB Class B

(Frankfurt:BIOA.B)

Select Model
Select Model
Select Model
Outperform 76 (OpenAI - 4o)
Rating:76Outperform
Price Target:
kr328.00
▲(10.22% Upside)
BioArctic AB Class B's overall stock score is driven by strong financial performance and positive technical indicators. The company's high profitability and efficient operations are significant strengths, while the bullish technical trend supports a positive outlook. The valuation is reasonable, though the lack of a dividend yield may deter some investors. Attention to cash flow growth and maintaining equity levels will be crucial for sustaining long-term success.

BioArctic AB Class B (BIOA.B) vs. iShares MSCI Sweden ETF (EWD)

BioArctic AB Class B Business Overview & Revenue Model

Company DescriptionBioArctic AB Class B (BIOA.B) is a biotechnology company based in Sweden, specializing in the development of innovative therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company focuses on advancing treatment options through its novel drug candidates and has a strong pipeline, which includes both proprietary products and collaborations with major pharmaceutical companies. BioArctic's core offerings include antibody-based therapies aimed at targeting key mechanisms involved in neurodegeneration.
How the Company Makes MoneyBioArctic generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on sales of developed products. The company's revenue model is built on the successful advancement of its drug candidates through clinical trials, leading to licensing agreements or joint ventures. Additionally, BioArctic may receive funding through grants or public funding aimed at supporting research in biotechnology and neurodegenerative disease therapies. The company's strategic collaborations with industry leaders enhance its financial position and expand its market reach, contributing to its overall earnings.

BioArctic AB Class B Financial Statement Overview

Summary
BioArctic AB Class B demonstrates strong financial performance with high profitability and revenue growth. The balance sheet is robust with low debt and high equity, but cash flow volatility poses a risk.
Income Statement
85
Very Positive
BioArctic AB Class B has shown remarkable improvement in its financial performance over the years, especially in the latest TTM period. The company has achieved a high gross profit margin and net profit margin, indicating strong profitability. Significant revenue growth and positive EBIT and EBITDA margins further underscore its financial health. However, past periods of negative margins highlight potential risks in sustaining growth.
Balance Sheet
78
Positive
The balance sheet reflects a strong equity position with a low debt-to-equity ratio, indicating financial stability. The company maintains a high equity ratio, demonstrating effective capital management. However, a consistent increase in liabilities over the years needs monitoring to ensure sustained balance sheet strength.
Cash Flow
70
Positive
While the company has shown improvement in free cash flow, the negative operating cash flow in the latest TTM period is concerning. The free cash flow to net income ratio suggests efficient cash management, but the high fluctuations in cash flows over the years indicate potential volatility in future cash generation.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.86B257.35M616.00M228.29M23.15M62.35M
Gross Profit1.81B230.37M526.37M153.97M-31.92M12.11M
EBITDA1.21B-165.13M295.29M4.22M-126.42M-74.58M
Net Income1.07B-177.08M229.25M-11.18M-119.79M-68.52M
Balance Sheet
Total Assets2.33B1.11B1.19B858.31M897.73M1.05B
Cash, Cash Equivalents and Short-Term Investments1.92B778.92M1.11B805.39M848.40M999.94M
Total Debt48.99M54.23M4.98M10.04M15.88M20.77M
Total Liabilities293.59M216.74M139.50M72.06M109.05M143.01M
Stockholders Equity2.04B894.94M1.05B786.24M788.68M907.30M
Cash Flow
Free Cash Flow1.05B-342.97M302.25M-44.38M-144.84M-104.81M
Operating Cash Flow1.05B-316.33M309.69M-31.64M-140.46M-92.34M
Investing Cash Flow-584.08M205.63M-507.49M-12.76M-4.41M-12.52M
Financing Cash Flow18.00M5.69M14.06M-2.81M-7.39M-6.60M

BioArctic AB Class B Technical Analysis

Technical Analysis Sentiment
Positive
Last Price297.60
Price Trends
50DMA
288.30
Positive
100DMA
244.56
Positive
200DMA
222.26
Positive
Market Momentum
MACD
2.26
Positive
RSI
50.66
Neutral
STOCH
26.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOA.B, the sentiment is Positive. The current price of 297.6 is below the 20-day moving average (MA) of 300.51, above the 50-day MA of 288.30, and above the 200-day MA of 222.26, indicating a neutral trend. The MACD of 2.26 indicates Positive momentum. The RSI at 50.66 is Neutral, neither overbought nor oversold. The STOCH value of 26.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BIOA.B.

BioArctic AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
kr25.79B24.1372.22%521.22%
$7.86B-0.30-43.30%2.27%22.53%-2.21%
€1.09B-41.54%0.57%
kr2.62B-55.23%-92.57%-7.72%
kr3.33B-3.7720.12%40.54%
$1.83B-6.27-28.70%382.81%23.87%
kr592.94M-275.87%38.99%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:BIOA.B
BioArctic AB Class B
294.40
136.50
86.45%
SE:HNSA
Hansa Biopharma AB
32.70
-5.16
-13.63%
SE:BINV
BioInvent International AB
28.30
-18.00
-38.88%
SE:VICO
Vicore Pharma Holding AB
11.02
2.79
33.90%
SE:XSPRAY
Xspray Pharma AB
25.75
-32.58
-55.86%
SE:CANTA
Cantargia AB
3.04
0.06
1.88%

BioArctic AB Class B Corporate Events

Health Canada Approves Leqembi for Early Alzheimer’s Treatment
Oct 27, 2025

Health Canada has authorized Leqembi (lecanemab) for treating early Alzheimer’s disease in patients with mild cognitive impairment or mild dementia. This approval marks a significant milestone as Leqembi is the first treatment in Canada targeting the disease’s underlying cause, potentially impacting the Alzheimer’s treatment landscape and offering new hope to patients and caregivers.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic AB Announces Formation of Nomination Committee for 2026 AGM
Oct 17, 2025

BioArctic AB has announced the formation of its Nomination Committee, which includes representatives from its three largest shareholders: Demban AB, Ackelsta AB, and The Fourth Swedish National Fund. This committee, representing a significant portion of the company’s shares and votes, will prepare proposals for the 2026 Annual General Meeting, impacting the company’s governance and strategic direction.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Launches Leqembi Treatment for Alzheimer’s in the Nordics
Oct 14, 2025

BioArctic AB has announced the first treatment of a patient with Leqembi in Finland, marking a significant milestone in its efforts to address early Alzheimer’s disease in the Nordics. The approval and implementation of Leqembi, which targets amyloid-beta protofibrils and amyloid plaque, represent a strategic advancement for BioArctic as it seeks to expand its impact in the pharmaceutical industry and provide new treatment options for Alzheimer’s patients.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Alzheimer’s Treatment Recognized as Top Innovation by TIME
Oct 14, 2025

BioArctic AB’s partner Eisai announced that Leqembi Iqlik, a subcutaneous autoinjector formulation of lecanemab for Alzheimer’s treatment, has been recognized by TIME as one of the best innovations of 2025 in the Medical and Healthcare category. This recognition highlights the innovation’s impact on Alzheimer’s treatment and strengthens BioArctic’s position in the biopharmaceutical industry, potentially enhancing its market presence and stakeholder confidence.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Leqembi Iqlik Launches in U.S. for Alzheimer’s Maintenance
Oct 6, 2025

BioArctic AB’s partner, Eisai, has launched Leqembi Iqlik, a subcutaneous injection for Alzheimer’s maintenance treatment in the U.S., offering a convenient at-home option for patients with early-stage Alzheimer’s. This development is expected to streamline treatment pathways, reduce healthcare resource demands, and enhance patient convenience, potentially strengthening BioArctic’s market position in Alzheimer’s therapies.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Leqembi® Gains Approval for Alzheimer’s Maintenance Treatment in China
Sep 29, 2025

BioArctic AB’s partner Eisai announced that Leqembi® (lecanemab) has been approved for once every four weeks intravenous maintenance treatment for early Alzheimer’s disease by China’s National Medical Products Administration. This approval marks a significant advancement in Alzheimer’s treatment, as Leqembi is the only approved therapy targeting both amyloid plaque and protofibrils, potentially impacting the disease’s progression. The approval strengthens BioArctic’s market position and offers new opportunities for commercialization in China, benefiting stakeholders involved in Alzheimer’s disease treatment.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Leqembi Approved for Early Alzheimer’s Treatment in Australia
Sep 24, 2025

BioArctic AB announced that the Therapeutic Goods Administration (TGA) of Australia has approved Leqembi® for treating early Alzheimer’s disease in specific patient groups. This approval marks a significant milestone following a review process initiated by Eisai, BioArctic’s partner, after an initial rejection. The approval strengthens BioArctic’s and Eisai’s position in the Alzheimer’s treatment market, allowing them to expand their commercialization efforts, particularly in the Nordic region.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic CEO Gunilla Osswald Honored as Uppsala University’s Alumnus of the Year 2025
Sep 9, 2025

Gunilla Osswald, CEO of BioArctic AB, has been named Uppsala University’s Alumnus of the Year 2025, acknowledging her visionary leadership and contributions to science and technology. This recognition highlights her role in developing lecanemab, a groundbreaking Alzheimer’s treatment, and underscores her influence as a role model, particularly for women in STEM fields, reinforcing BioArctic’s position as a leader in neurodegenerative disease research.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Founders to Divest Minor Shareholdings
Sep 3, 2025

BioArctic AB announced that its founders, Lars Lannfelt and Pär Gellerfors, plan to divest a minor portion of their shareholdings. This move is part of the company’s regulatory obligations and may impact the company’s stock dynamics, though it is not expected to significantly alter its operational or strategic direction.

The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK347.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic and Eisai Advance Alzheimer’s Treatment with FDA Submission
Sep 3, 2025

BioArctic AB’s partner, Eisai, has initiated a rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for early Alzheimer’s disease treatment, under Fast Track status. This development could allow patients to receive treatment at home, offering a more convenient alternative to intravenous dosing, potentially reducing healthcare resource demands and streamlining Alzheimer’s treatment.

The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

FDA Approves BioArctic’s Subcutaneous Alzheimer’s Treatment
Aug 29, 2025

BioArctic AB, in partnership with Eisai, announced the FDA approval of Leqembi IQKLIK, a subcutaneous injection for maintenance dosing in early Alzheimer’s disease. This approval marks a significant advancement in Alzheimer’s treatment, offering a more convenient administration method that could enhance patient access and reduce healthcare resource demands, potentially improving the company’s market position and stakeholder value.

The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic AB Sees Growth with Leqembi® and Novartis Partnership
Aug 28, 2025

BioArctic AB reported a significant increase in royalties from Leqembi® and announced a new partnership with Novartis, which includes an upfront payment and potential future milestones. The company’s operations are bolstered by strong sales forecasts for Leqembi®, recent marketing authorizations, and promising study results, positioning them well in the neurodegenerative disease treatment market.

The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Partners with Novartis for Neurodegeneration Treatment
Aug 26, 2025

BioArctic AB has entered a collaboration and license agreement with Novartis Pharma AG, leveraging its BrainTransporter technology for potential neurodegeneration treatments. The deal includes a $30 million upfront payment, with potential future milestones and royalties, highlighting BioArctic’s strategic positioning in the neurodegenerative treatment market and its potential for further partnerships.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic’s Leqembi Launches in EU, Targeting Alzheimer’s Disease
Aug 25, 2025

BioArctic AB’s partner Eisai has launched Leqembi in the EU, starting with Austria and Germany, following its approval by the European Commission as the first therapy targeting the underlying cause of Alzheimer’s disease. This launch marks a significant step in addressing the unmet need for treatments that slow the progression of Alzheimer’s, potentially impacting the company’s market position and providing new options for patients and healthcare providers.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic AB to Present Q2 2025 Financial Report
Aug 21, 2025

BioArctic AB announced it will release its second quarter report for 2025 on August 28, followed by an audiocast and teleconference for investors, analysts, and media. This event will provide insights into the company’s financial performance and strategic direction, potentially impacting investor perceptions and market positioning.

The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK243.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.

BioArctic Reports Strong Q2 2025 Leqembi Sales Boost
Jul 31, 2025

BioArctic AB announced that sales of Leqembi® totaled 23.1 billion yen in the second quarter of 2025, resulting in a significant royalty increase of approximately 280% compared to the previous year. The sales figures included a one-time stockpiling effect in China due to tariff risks, with global sales excluding this effect amounting to 17.8 billion yen. This financial performance underscores BioArctic’s strengthened market position and potential for future growth in the Alzheimer’s treatment sector.

BioArctic’s Lecanemab Shows Promising Long-Term Benefits in Alzheimer’s Treatment
Jul 31, 2025

BioArctic AB’s partner, Eisai, presented new data at the Alzheimer’s Association International Conference 2025, highlighting the efficacy and safety of lecanemab in treating early-stage Alzheimer’s disease. The findings from the phase 3 Clarity AD study and real-world evidence suggest that lecanemab can slow disease progression and maintain cognitive function over four years, with a consistent safety profile, offering promising long-term benefits for patients.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 06, 2025